FGFR4 Inhibitors
2 drugsAbout FGFR4
Fibroblast growth factor receptor 4 (FGFR4) is a receptor tyrosine kinase involved in cell growth, differentiation, and angiogenesis. It is activated by fibroblast growth factors and plays a role in embryonic development and tissue repair.
FGFR4 is a therapeutic target in oncology and other areas, as evidenced by two FDA-approved drugs. While direct genetic evidence linking FGFR4 to specific diseases is currently unavailable, its druggability makes it an attractive target.
FGFR4 is targeted by two FDA-approved small molecule inhibitors: LENVIMA (EISAI INC) and BALVERSA (Johnson & Johnson). LENVIMA has 5 indications, while BALVERSA has 1, spanning oncology and other therapeutic areas.
Top FGFR4 Drugs
The competitive landscape for FGFR4 inhibitors includes EISAI INC and Johnson & Johnson.
The FGFR4 market is concentrated, so new entrants should focus on underserved indications or novel mechanisms.
FGFR4 Drug Modality Landscape
Modalities
Routes of Administration
FGFR4 is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing small molecule inhibitors.
FGFR4 Clinical Trials 324 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on FGFR4. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 78 | 43 | 8 | 27 | 84% |
| Phase 2 | 196 | 47 | 28 | 118 | 63% |
| Phase 3 | 46 | 21 | 4 | 21 | 84% |
| Phase 4 | 4 | 2 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
FGFR4 Drug Approval Timeline (2015 - 2019)
The first FGFR4-targeting drug, LENVIMA, was approved in 2015, and the most recent, BALVERSA, in 2019.
The recent approval of BALVERSA suggests continued interest in FGFR4, but market saturation may be approaching.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 134 (28 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on FGFR4. A trial counts if an approved drug acting on FGFR4 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.